In a groundbreaking move for the cryptocurrency sector, Sonnet BioTherapeutics has received shareholder approval for a merger with Hyperliquid Strategies and Rorschach I. This strategic alliance, confirmed on December 2, 2025, aims to create a publicly traded vehicle focused on HYPE-centric crypto treasury management. According to the assessment of specialists presented in the publication, this merger is expected to significantly enhance the operational capabilities of both companies.
Major Shift for Sonnet
The merger signifies a major shift for Sonnet, a company previously listed on NASDAQ, as it ventures into the realm of digital assets. With a goal of establishing a treasury with reserves targeting 1 billion in HYPE, this initiative is set to enhance the company's portfolio and market presence.
Hyperliquid's Role in the Market
Hyperliquid is poised to become a key player in the HYPE digital asset treasury reserve market, which could have far-reaching implications for the cryptocurrency landscape. As the market evolves, this merger may influence investment strategies and the overall perception of digital assets among traditional investors.
In a related development, Mono Protocol has successfully completed its smart contract audit with CertiK, enhancing its credibility in the blockchain sector. For more details, see more.
